HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hisato Kawakami Selected Research

patritumab

1/2019Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
1/2016HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy.
12/2014The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hisato Kawakami Research Topics

Disease

45Neoplasms (Cancer)
10/2022 - 05/2009
23Stomach Neoplasms (Stomach Cancer)
07/2022 - 05/2012
18Colorectal Neoplasms (Colorectal Cancer)
10/2022 - 04/2011
8Disease Progression
10/2022 - 01/2016
7Esophageal Neoplasms (Esophageal Cancer)
10/2022 - 08/2015
7Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 07/2014
5Esophageal Squamous Cell Carcinoma
10/2022 - 01/2019
5Adenocarcinoma
08/2022 - 01/2020
4Breast Neoplasms (Breast Cancer)
02/2020 - 10/2014
3Neoplasm Metastasis (Metastasis)
10/2021 - 05/2012
3Microsatellite Instability
02/2021 - 07/2015
3Squamous Cell Carcinoma of Head and Neck
09/2019 - 12/2013
2Oropharyngeal Neoplasms
10/2021 - 01/2018
2Melanoma (Melanoma, Malignant)
01/2021 - 01/2016
2Pneumonia (Pneumonitis)
01/2020 - 01/2016
2Deglutition Disorders (Dysphagia)
01/2019 - 10/2017
2Diarrhea
12/2018 - 10/2014
2Carcinoma (Carcinomatosis)
10/2017 - 04/2015
2Colonic Neoplasms (Colon Cancer)
12/2016 - 09/2015
2Chromosomal Instability (Chromosome Stability)
12/2015 - 07/2015
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022
1Colitis
01/2022
1Weight Loss (Weight Reduction)
11/2021
1Hand-Foot Syndrome
10/2021
1Fibrosis (Cirrhosis)
01/2021

Drug/Important Bio-Agent (IBA)

10NivolumabIBA
01/2022 - 01/2017
7Cisplatin (Platino)FDA LinkGeneric
08/2022 - 05/2012
7Docetaxel (Taxotere)FDA Link
07/2022 - 08/2015
7LigandsIBA
01/2021 - 12/2014
7Pharmaceutical PreparationsIBA
01/2021 - 05/2009
6Fluorouracil (Carac)FDA LinkGeneric
10/2022 - 08/2015
6Oxaliplatin (Eloxatin)FDA LinkGeneric
08/2022 - 01/2020
6Tyrosine Kinase InhibitorsIBA
01/2022 - 01/2013
6Biomarkers (Surrogate Marker)IBA
10/2021 - 05/2016
5Capecitabine (Xeloda)FDA Link
01/2022 - 05/2012
5Immune Checkpoint InhibitorsIBA
01/2022 - 01/2019
5Neuregulin-1 (Neuregulin 1)IBA
09/2019 - 12/2014
4pembrolizumabIBA
08/2022 - 01/2016
4Monoclonal AntibodiesIBA
01/2022 - 01/2016
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
06/2021 - 09/2015
4Cetuximab (Erbitux)FDA Link
06/2021 - 08/2011
4Trastuzumab (Herceptin)FDA Link
02/2020 - 12/2016
3PlatinumIBA
10/2022 - 10/2017
3human ERBB2 proteinIBA
08/2022 - 12/2019
3Irinotecan (Camptosar)FDA LinkGeneric
07/2022 - 01/2021
3Bevacizumab (Avastin)FDA Link
03/2022 - 07/2020
3S-1 plus cisplatinIBA
10/2021 - 12/2018
3Paclitaxel (Taxol)FDA LinkGeneric
10/2021 - 10/2014
3Formaldehyde (Formol)FDA Link
01/2021 - 01/2013
3trastuzumab deruxtecanIBA
01/2021 - 12/2019
3ParaffinIBA
01/2021 - 01/2013
3Messenger RNA (mRNA)IBA
09/2019 - 07/2014
3ErbB Receptors (EGF Receptor)IBA
09/2019 - 01/2016
3patritumabIBA
01/2019 - 12/2014
3nedaplatinIBA
01/2019 - 12/2013
3Small Interfering RNA (siRNA)IBA
01/2018 - 04/2015
2AntibodiesIBA
10/2022 - 07/2016
2B7-H1 AntigenIBA
08/2022 - 01/2022
2RamucirumabIBA
07/2022 - 12/2020
2patritumab deruxtecanIBA
01/2022 - 01/2020
2IpilimumabIBA
01/2022 - 02/2021
2Proteins (Proteins, Gene)FDA Link
01/2021 - 12/2019
2cobimetinibIBA
01/2018 - 12/2016
2Alanine Transaminase (SGPT)IBA
01/2017 - 01/2016
2Calcibiotic Root Canal SealerIBA
12/2015 - 07/2015
1taxaneIBA
10/2022
1Notch ReceptorsIBA
10/2022
1Cytotoxins (Cytolysins)IBA
03/2022
1RNA (Ribonucleic Acid)IBA
01/2022
1sotorasibIBA
10/2021
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
10/2021
1AlbuminsIBA
10/2021
1C-Reactive ProteinIBA
10/2021
1regorafenibIBA
10/2021
1encorafenibIBA
06/2021
1binimetinibIBA
06/2021
1MORAb-202IBA
01/2021
1Immunoconjugates (Immunoconjugate)IBA
01/2021
1nintedanibIBA
01/2021
1Topoisomerase I InhibitorsIBA
01/2021
1fms-Like Tyrosine Kinase 3IBA
01/2021
1Panitumumab (Vectibix)FDA Link
01/2021
1Folic Acid (Vitamin M)FDA LinkGeneric
01/2021
1ThymidineIBA
12/2020
1Drug CombinationsIBA
12/2020
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
12/2020
1trifluridine tipiracil drug combinationIBA
12/2020

Therapy/Procedure

33Therapeutics
10/2022 - 07/2014
24Drug Therapy (Chemotherapy)
10/2022 - 04/2011
5Combination Drug Therapy (Combination Chemotherapy)
03/2022 - 12/2019
5Immunotherapy
01/2022 - 01/2019
4Adjuvant Chemotherapy
07/2022 - 07/2015
3Gastrectomy
07/2022 - 01/2020
3Aftercare (After-Treatment)
07/2019 - 10/2017
2Radiotherapy
10/2021 - 01/2018
2Precision Medicine
06/2021 - 01/2021
2Neoadjuvant Therapy
12/2019 - 12/2018
1Lymph Node Excision (Lymph Node Dissection)
07/2022
1Hepatectomy
01/2021
1Transplantation
12/2020